ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

The stock's rise snapped a four-day losing streak.

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals Inc. closed 49.58% below its 52-week high of $1,211.20, which the company achieved on August 27th.